Perfluorohexyloctane ophthalmic solution: a review of a prescription treatment for dry eye disease that directly targets tear evaporation

References

• Morthen MK, Magno MS, Utheim TP, et al. The vision-related burden of dry eye. Ocul Surf. 2022;23:207–215. doi: 10.1016/j.jtos.2021.10.007
   PubMed Web of Science ®Google Scholar
• Sun M, Moreno IY, Dang M, et al. Meibomian gland dysfunction: what have animal models taught us? Int J Mol Sci. 2020;21(22):8822. doi: 10.3390/ijms21228822
   PubMed Web of Science ®Google Scholar
• Dana R, Bradley JL, Guerin A, et al. Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age United States health care system. Am J Ophthalmol. 2019;202:47–54. doi: 10.1016/j.ajo.2019.01.026
   PubMed Web of Science ®Google Scholar
• Tsubota K, Pflugfelder SC, Liu Z, et al. Defining dry eye from a clinical perspective. Int J Mol Sci. 2020;21(23):9271. doi: 10.3390/ijms21239271
   PubMed Web of Science ®Google Scholar
• Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017 Oct;15(4):802–812. doi: 10.1016/j.jtos.2017.08.003
   PubMed Web of Science ®Google Scholar
• McMonnies CW. Aqueous deficiency is a contributor to evaporation-related dry eye disease. Eye Vis (Lond). 2020;7(1):6. doi: 10.1186/s40662-019-0172-z
   PubMedGoogle Scholar
• Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472–478. doi: 10.1097/ICO.0b013e318225415a
   PubMed Web of Science ®Google Scholar
• Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmol. 2017;124(11S):S20–6. doi: 10.1016/j.ophtha.2017.05.031
   PubMedGoogle Scholar
• Covita A, Chen MH, Leahy C. Correlation between meibomian gland appearance and tear breakup time using a slit scanning ophthalmoscope. Invest Ophthalmol Vis Sci. 2019;60(9):6793.
   Web of Science ®Google Scholar
• Kim WJ, Ahn YJ, Kim MH, et al. Lipid layer thickness decrease due to meibomian gland dysfunction leads to tear film instability and reflex tear secretion. Ann Med. 2022;54(1):893–899. doi: 10.1080/07853890.2022.2056238
   PubMed Web of Science ®Google Scholar
• Li J, Ma J, Hu M, et al. Assessment of tear film lipid layer thickness in patients with Meibomian gland dysfunction at different ages. BMC Ophthalmol. 2020;20(1):394. doi: 10.1186/s12886-020-01667-8
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Kurata F, Epitropoulos AT, et al. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol. 2023;252:265–274. doi: 10.1016/j.ajo.2023.03.008
   PubMed Web of Science ®Google Scholar
• Mason L, Jafri S, Dortonne I, et al. Emerging therapies for dry eye disease. Expert Opin Emerg Drugs. 2021 Dec;26(4):401–413. doi: 10.1080/14728214.2021.2011858
   PubMed Web of Science ®Google Scholar
• Vittitow J, Kissling R, DeCory H, et al. In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease. Curr Ther Res. 2023;98:100704. doi: 10.1016/j.curtheres.2023.100704
   PubMed Web of Science ®Google Scholar
• Hall JQ Jr., Ridder WH 3rd, Nguyen AL, et al. Visual effect and residence time of artificial tears in dry eye subjects. Optom Vis Sci. 2011;88(7):872–880. doi: 10.1097/OPX.0b013e31821b0b2c
   PubMed Web of Science ®Google Scholar
• Agarwal P, Craig JP, Rupenthal ID. Formulation considerations for the management of dry eye disease. Pharmaceutics. 2021;13(2):207. doi: 10.3390/pharmaceutics13020207
   PubMed Web of Science ®Google Scholar
• White DE, Zhao Y, Ogundele A, et al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin Ophthalmol. 2019;13:2285–2292. doi: 10.2147/OPTH.S226168
   PubMed Web of Science ®Google Scholar
• Bausch + Lomb. Bausch + Lomb and Novaliq announce FDA approval of MIEBO™ (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease. Bausch + Lomb News Releases. 2023 [cited 2023 May 28]. Available from: https://www.bausch.com/news/releases/?id=156
   Google Scholar
• MIEBO [package insert]. Bridgewater NJ: Bausch & Lomb Incorporated. 2023. https://www.bausch.com/globalassets/pdf/packageinserts/pharma/miebo-package-insert.pdf
   Google Scholar
• Steven P, Scherer D, Krosser S, et al. Semifluorinated alkane eye drops for treatment of dry eye disease—a prospective, multicenter noninterventional study. J Ocul Pharmacol Ther. 2015;31(8):498–503. doi: 10.1089/jop.2015.0048
   PubMed Web of Science ®Google Scholar
• Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmol. 2023;130(5):516–524. doi: 10.1016/j.ophtha.2022.12.021
   PubMed Web of Science ®Google Scholar
• Habbe KJ, Frings A, Saad A, et al. The influence of a mineral oil cationic nanoemulsion or perfluorohexyloctane on the tear film lipid layer and higher order aberrations. PLoS One. 2023;18(1):e0279977. doi: 10.1371/journal.pone.0279977
   PubMed Web of Science ®Google Scholar
• Drug approval package: MIEBO: United States Food and drug administration. 2023 [updated 2023 Jun 20; cited 2023 Sep 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216675Orig1s000TOC.cfm
   Google Scholar
• Stolowich N, Vittitow J, Kissling R, et al. Oxygen-carrying capacity of perfluorohexyloctane, a novel eye drop for dry eye disease. Curr Ther Res Clin Exp. 2023;98:100705. doi: 10.1016/j.curtheres.2023.100705
   PubMed Web of Science ®Google Scholar
• Krösser S, Spencer E, Grillenberger R, et al. Ocular and systemic distribution of 14C-perfluorohexyloctane following topical ocular administration to rabbits. Invest Ophthalmol Vis Sci. 2018;59:2656.
   Web of Science ®Google Scholar
• Li S, Tian Q, Ding G, et al. The impact of different oxygen delivery methods on corneal epithelial repair after injury. J Ophthalmol. 2022;2022:3260087. doi: 10.1155/2022/3260087
   PubMed Web of Science ®Google Scholar
• Vittitow J, Protzko E, Segal BA, et al. Long-term safety and efficacy of NOV03 (perfluorohexyloctane) for the treatment of patients with dry eye disease associated with meibomian gland dysfunction: the KALAHARI study. Invest Ophthalmol Vis Sci. 2023;64:3995.
   Web of Science ®Google Scholar
• Tauber J, Wirta DL, Sall K, et al. A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease. Cornea. 2021;40(9):1132–1140. doi: 10.1097/ICO.0000000000002622
   PubMed Web of Science ®Google Scholar
• Tian L, Gao Z, Zhu L, et al. Perfluorohexyloctane eye drops for dry eye disease associated with meibomian gland dysfunction in Chinese patients: a randomized clinical trial. JAMA Ophthalmol. 2023;141(4):385–392. doi: 10.1001/jamaophthalmol.2023.0270
   PubMed Web of Science ®Google Scholar
• Schmidl D, Bata AM, Szegedi S, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther. 2020;36(3):154–161. doi: 10.1089/jop.2019.0092
   PubMed Web of Science ®Google Scholar
• Agarwal P, Khun D, Krosser S, et al. Evaluating the lubricating effect of semifluorinated alkanes on the ocular surface. Invest Ophthalmol Vis Sci. 2018;59:3282.
   Web of Science ®Google Scholar
• Novel drug approvals for 2023: the United States Food & drug administration. 2023 [updated 2023 Jul 25; cited 2023 Jul 27]. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-431therapeutic-biological-products/novel-drug-approvals-2023
   Google Scholar
• Borchman D, Vittitow J, Ewurum A, et al. Spectroscopic study of perfluorohexyloctane—human meibum interactions. Ophthalmol Vis Sci. 2022;63(7):1525–A0250.
   Web of Science ®Google Scholar